On the basis of MSCs homing toward tumor region and the combination of CD20 antibody to CD20-positive B cell lymphocytes, UCMSCs-Tandab(IL-6/CD20) could effectively inhibit the viability of lymphoma cells in the ex vivo experiment. This evidence concerns the gene IL6 and neoplasm.